First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

被引：23
|
作者：
Baselga, J.
Bradbury, I.
Eidtmann, H.
Di Cosimo, S.
Aura, C.
De Azambuja, E.
Gomez, H.
Dinh, P.
Fauria, K.
Van Dooren, V.
Paoletti, P.
Goldhirsch, A.
Chang, T-W
Lang, I.
Untch, M.
Gelber, R. D.
Piccart-Gebhart, M.
机构：
[1] Vall dHebron Univ Hosp, NeoALTTO Study Team, Barcelona, Spain
[2] FSS Ltd, Kincraig, Scotland
[3] Univ Hosp Kiel, Kiel, Germany
[4] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain
[5] SOLTI Spanish Breast Canc Res Grp, Barcelona, Spain
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] Breast European Adjuvant Study Team, Brussels, Belgium
[8] Inst Nacl Enfermedades Neoplas, Lima, Peru
[9] Breast Int Grp, Brussels, Belgium
[10] GlaxoSmithKline, Collegeville, PA USA
[11] European Inst Oncol, Milan, Italy
[12] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[13] Natl Inst Oncol, Budapest, Hungary
[14] Charite, Acad Hosp, D-13353 Berlin, Germany
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-S3-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-3
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Rozas, Ashley Alarcon
    Matos Neto, Joao Nunes
    Caleffi, Maira
    Vinholes, Jeferson J. F.
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina Maria
    Osborne, C. Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)
    Piccart-Gebhart, M.
    Holmes, A. P.
    de Azambuja, E.
    Di Cosimo, S.
    Swaby, R.
    Untch, M.
    Jackisch, C.
    Lang, I.
    Smith, I.
    Boyle, F.
    Xu, B.
    Barrios, C.
    Gelber, R.
    Eidtmann, H.
    Baselga, J.
    CANCER RESEARCH, 2013, 73
  • [33] Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
    Tamas Hickish
    Ajay Mehta
    Mei-Ching Liu
    Chiun-Sheng Huang
    Rajendra Singh Arora
    Yuan-Ching Chang
    Youngsen Yang
    Vladimir Vladimirov
    Minish Jain
    Janice Tsang
    Karine Pemberton
    Behbood Sadrolhefazi
    Xidong Jin
    Ling-Ming Tseng
    Breast Cancer Research and Treatment, 2022, 192 : 593 - 602
  • [34] Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
    Hickish, Tamas
    Mehta, Ajay
    Liu, Mei-Ching
    Huang, Chiun-Sheng
    Arora, Rajendra Singh
    Chang, Yuan-Ching
    Yang, Youngsen
    Vladimirov, Vladimir
    Jain, Minish
    Tsang, Janice
    Pemberton, Karine
    Sadrolhefazi, Behbood
    Jin, Xidong
    Tseng, Ling-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 593 - 602
  • [35] Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
    Huang, Liang
    Chen, Sheng
    Yang, Wentao
    Xu, Binghe
    Huang, Tao
    Yang, Hongjian
    Zheng, Hong
    Wang, Yongsheng
    Song, Erwei
    Zhang, Jin
    Cui, Shude
    Pang, Da
    Tang, Lili
    Lei, Yutao
    Geng, Cuizhi
    Shao, Zhiming
    ONCOTARGET, 2015, 6 (21) : 18683 - 18692
  • [36] Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)
    Di Cosimo, S.
    Campbell, C.
    Hazim, H. A., Jr.
    Curigliano, G.
    Criscitiello, C.
    Crescenzo, R.
    de la Pena, L.
    Piccart-Gebhart, M. J.
    Eidtmann, H.
    Baselga, J.
    de Azambuja, E.
    CANCER RESEARCH, 2016, 76
  • [37] Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
    Tanioka, M.
    Fan, C.
    Carey, L. A.
    Hyslop, T.
    Pitcher, B. N.
    Parker, J. A.
    Hoadley, K. A.
    Henry, N. L.
    Tolaney, S.
    Dang, C.
    Krop, I. E.
    Harris, L.
    Berry, D. A.
    Mardis, E.
    Perou, C. M.
    Winer, E. P.
    Hudis, C. A.
    CANCER RESEARCH, 2017, 77
  • [38] Letter to the editor on 'Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial'
    Barry, P. A.
    Schiavon, G.
    MacNeill, F. A.
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 909 - 910
  • [39] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [40] TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Niravath, Polly
    Wang, Tao
    Rexer, Brent N.
    Forero, Andres
    Wolff, Antonio C.
    Nanda, Rita
    Storniolo, Anna M.
    Krop, Ian
    Goetz, Matthew P.
    Nangia, Julie R.
    Jiralerspong, Sao
    Pavlick, Anne
    Veeraraghavan, Jamunarani
    De Angelis, Carmine
    Gutierrez, Carolina
    Schiff, Rachel
    Hilsenbeck, Susan G.
    Osborne, C. Kent
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 821 - 827
12345